Older individuals may require more attention if they receive high cumulative oral corticosteroid doses with gaps between their prescriptions, according to recent findings, given that they may not be given the chance to get fracture preventative care.1
Summary of Findings
- The research was condcuted to examine the relationship between oral corticosteroid prescriptions and fracture preventive care and major osteoporotic fractures.
- Those with high-intensity oral corticosteroid prescriptions received more fracture preventive care compared to those with low-intensity prescriptions.
- The investigators found no significant difference in major osteoporotic fracture rates between high- and low-intensity oral corticosteroid prescription groups.
- Sensitivity analyses showed that a higher cumulative corticosteroid dose in a shorter time frame or with fewer prescriptions led to increased fracture preventive care prescribing.
The study’s investigators note that oral corticosteroid prescriptions are frequently given out in brief and discontinuous bursts to address flares of relapsing-remitting diseases, such as eczema, and chronic obstructive pulmonary disease (COPD), among others.2
The research was conducted with the overall goal of examining and then mitigating potential gaps in preventative care to reduce the overall high rates of mortality linked to fractures, and the research was authored by Aaron M. Drucker, MD, ScM, from Women’s College Hospital in Toronto, Canada.3
“The objective of this study was to determine whether oral corticosteroid prescribing patterns were differentially associated with receiving guideline-recommended fracture preventive care among older adults with eczema, asthma, or COPD,” Drucker and colleagues wrote.
Background and Findings
The investigators’ cohort study involved use of 65,195 individuals whose electronic medical record information was drawn from the UK’s Clinical Practice Research Datalink, with the data being from January of 1998 to January of 2020. Additionally, 28,674 individuals were included with health administrative data featured in ICES in Ontario, Canada from April of 2002 to September of 2020.
The team’s research assessed adults who were aged 66 years or older and had been given prescriptions for oral corticosteroids to address conditions including asthma, eczema, or COPD. The individuals’ prescriptions needed a cumulative prednisolone equivalent dose of 450 mg or more and to be within a 6-month timeframe.
The investigators’ analysis of data was initiated from October of 2020 to September of 2022. In terms of exposures, the study participants were labeled based upon the rate of crossing the 450-mg cumulative oral corticosteroid threshold.
The individuals who were able to cross this particular threshold in fewer than 90 days were given a label of having ‘high-intensity prescriptions,’ while those who needed 90 days or more were considered to have ‘low-intensity prescriptions.’ Several different alternative exposure definitions were examined in the team’s sensitivity analyses.